- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04485845
Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression
Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression
Several crosssectional and prospective studies have shown that metabolic syndrome and its related components are associated with both prevalent and incident CKD .
Although the mechanisms for these cardiovascular benefits of Metformin and vildagliptin remain unclear, they extend well beyond glycemic lowering, and therefore are probably best considered diverse "cardiometabolic" pharmaceuticals rather than simply type 2 diabetes drugs.
Metformin and vildagliptin have known vasculoprotective actions, but the value of these drugs on drug-naïve diabetic patients during 24 week use warrants investigation. The investigator's purpose was to observe their effects on weight control, Cardiometabolic Risk Factors, Metabolic Syndrome risk, and diabetic nephrooathy Progression.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Dalia Zaafar, PhD
- Phone Number: 00201117922833
- Email: dalia.zaffar@pharm.mti.edu.eg
Study Contact Backup
- Name: soha hassanin, phd
- Email: phsoha@hotmail.com
Study Locations
-
-
-
Cairo, Egypt, 11311
- Recruiting
- National Diabetes & Endocrinology Institute
-
Contact:
- dalia zaafar, phd
-
Contact:
- soha hassanin, phd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- men or women 40-70 years of age
- body mass index be-tween≥22 and ≤40 kg/m2.
- DM with an HbA1c ≥ 7
Exclusion Criteria:
(1) pregnant or nursing women; (2) chronic (>7 consecutive days) oral, parenteral or intra-articular corticosteroid treatment within 8 weeks prior to Visit 1 (3) history or evidence of major hepatopathy (aspartate aminotransferase or alanineaminotransferase activities > 2.5 times the upper limit of normal) (4) ischemic heart disease or cerebrovascular disease (5) creatinine level > 0.133 mmol/L (6) major diabetes complications (chronic renal insufficiency, proliferative retinopathy and stroke); (7) extreme dyslipidemia, such as familial hypercholesterolaemia
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: metformin treated group
A group of patients treated with a daily dose of metformin
|
used to treat hypertension in metabolic syndrome patients and as a renal protector
antihyperglycemic drug for elevated plasma glucose level and help in weight loss for patients suffering from diabetes or metabolic syndrome
|
Experimental: vildagliptin treated group
A group of patients treated with a daily dose of vildagliptin
|
used to treat hypertension in metabolic syndrome patients and as a renal protector
to compare the effect of both metformin and vildagliptin on the progression of diabetes and metabolic complications and risk factors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression of metabolic syndrome complications
Time Frame: 24 weeks
|
investigate the effect of antidiabetic drugs on improving patients' cases and reduce complcations of metablic syndrome and that will be assessed by measuring glucose serum levels, insulin plasma levels to calculate insulin resistance by HOMA-ir
|
24 weeks
|
estimation of metabolic syndrome deterioration
Time Frame: 24 weeks
|
study the effect of both antidiabetic drugs on blood pressure
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reduce nephropathic impairement
Time Frame: 24 weeks
|
study the impact of both metformin and vildagliptin on reducing kidney deterioration for patients suffering from metabolic syndrome and that can be assessed by measuring kidney function serologically using ELISA kits for each parameter
|
24 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dalia Zaafar, PhD, Lecturer of clinical pharmacology and toxicology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Disease
- Diabetes Mellitus
- Insulin Resistance
- Hyperinsulinism
- Diabetes Mellitus, Type 2
- Syndrome
- Metabolic Syndrome
- Renal Insufficiency
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Protease Inhibitors
- Dipeptidyl-Peptidase IV Inhibitors
- Angiotensin-Converting Enzyme Inhibitors
- Metformin
- Vildagliptin
- Captopril
Other Study ID Numbers
- IDE00218
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
Mayo ClinicCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on Captopril Tablets
-
University of CalgaryDr. Sandra DumanskiRecruitingHormone TherapyCanada
-
Rigshospitalet, DenmarkUnknown
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyTerminatedLung Cancer | Pulmonary Complications | Radiation FibrosisUnited States
-
National Taiwan University HospitalNovartisUnknown
-
Chongqing Medical UniversityChinese PLA General Hospital; Tianjin Medical University General Hospital; Chinese...Recruiting
-
Assistance Publique - Hôpitaux de ParisUnknownCOVID-19 | Coronavirus Infection | PneumoniaFrance
-
Instituto de Cardiologia do Rio Grande do SulCompleted
-
Wuhan UniversityRecruitingRadiotherapy Side Effect | Taking CaptoprilChina
-
Natural Wellness EgyptNot yet recruitingEssential Hypertension
-
Coordinación de Investigación en Salud, MexicoCompletedInflammation | End-stage Renal DiseaseMexico